BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J 2020;56:2001618. [PMID: 32631836 DOI: 10.1183/13993003.01618-2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Kitamura M, Sugimoto H. Clinically amyopathic dermatomyositis during the COVID-19 pandemic. Oxf Med Case Reports 2021;2021:omab061. [PMID: 34408884 DOI: 10.1093/omcr/omab061] [Reference Citation Analysis]
2 Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol 2021;12:773352. [PMID: 34745149 DOI: 10.3389/fimmu.2021.773352] [Reference Citation Analysis]
3 Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and Myositis: What We Know So Far. Curr Rheumatol Rep 2021;23:63. [PMID: 34216297 DOI: 10.1007/s11926-021-01023-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fatone MC. COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations? Curr Rheumatol Rev 2021;17:7-16. [PMID: 33019935 DOI: 10.2174/1573397116666201005122603] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mecoli CA, Yoshida A, Paik JJ, Lin CT, Danoff S, Hanaoka H, Rosen A, Christopher‐stine L, Kuwana M, Casciola‐rosen L. Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis. ACR Open Rheumatology. [DOI: 10.1002/acr2.11423] [Reference Citation Analysis]
6 Mehta P, Porter JC, Chambers RC, Isenberg DA, Reddy V. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Lancet Rheumatol 2020;2:e589-90. [PMID: 33521659 DOI: 10.1016/S2665-9913(20)30270-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 13.5] [Reference Citation Analysis]
7 Ruscitti P, Di Cola I, Di Muzio C, Italiano N, Ursini F, Giacomelli R, Cipriani P. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Autoimmun Rev 2022;:103114. [PMID: 35595050 DOI: 10.1016/j.autrev.2022.103114] [Reference Citation Analysis]
8 Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int 2021;41:1021-36. [PMID: 33774723 DOI: 10.1007/s00296-021-04819-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Seixas MLGA, Mitre LP, Shams S, Lanzuolo GB, Bartolomeo CS, Silva EA, Prado CM, Ureshino R, Stilhano RS. Unraveling Muscle Impairment Associated With COVID-19 and the Role of 3D Culture in Its Investigation. Front Nutr 2022;9:825629. [DOI: 10.3389/fnut.2022.825629] [Reference Citation Analysis]
10 Pauling JD, Christopher-Stine L. The aetiopathogenic significance, clinical relevance and therapeutic implications of vasculopathy in idiopathic inflammatory myopathy. Rheumatology (Oxford) 2021;60:1593-607. [PMID: 33458769 DOI: 10.1093/rheumatology/keaa816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 He C, Li W, Xie Q, Yin G. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review. Front Immunol 2022;12:820163. [DOI: 10.3389/fimmu.2021.820163] [Reference Citation Analysis]
12 Gono T, Okazaki Y, Kuwana M. Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology (Oxford) 2021:keab371. [PMID: 33890985 DOI: 10.1093/rheumatology/keab371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Khomari F, Nabi-Afjadi M, Yarahmadi S, Eskandari H, Bahreini E. Effects of Cell Proteostasis Network on the Survival of SARS-CoV-2. Biol Proced Online 2021;23:8. [PMID: 33618659 DOI: 10.1186/s12575-021-00145-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Selva-O'Callaghan A, Romero-Bueno F, Trallero-Araguás E, Gil-Vila A, Ruiz-Rodríguez JC, Sánchez-Pernaute O, Pinal-Fernández I. Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease. Curr Treatm Opt Rheumatol 2021;:1-15. [PMID: 34603940 DOI: 10.1007/s40674-021-00186-x] [Reference Citation Analysis]